We examined the effects of bone marrow transplantation (BMT) on immune-mediated inner ear diseases in MRL/Mp-lpr/lpr (MRL/lpr) mice, which manifest not only lupus nephritis but also sensorineural hearing loss (SNHL) at the age of 20 weeks. These mice were treated with cyclophosphamide (CY) and irradiation (5 Gy × 2), followed by the transplantation of bones plus bone marrow cells from allogeneic normal C57BL/6 mice at the age of 12 weeks. Hematolymphoid cells were reconstituted with donor-derived cells 3 months after BMT. Behçet's disease, 13, 14 Cogan's syndrome, 15, 16 and ulcerative colitis 17, 18 has been reported.
It has become widely recognized that autoimmune mechanisms are involved in inner ear diseases [1] [2] [3] such as steroidresponsive sensorineural hearing loss (SNHL) 4 and Méni-ère's disease, 5 as first proposed by McCabe in 1979. 1 Inner ear dysfunction causes various audiovestibular symptoms such as SNHL, tinnitus and vertigo. The presence of SNHL as a part of or in combination with systemic autimmune diseases such as systemic lupus erythematosus (SLE), [6] [7] [8] rheumatoid arthritis (RA), [9] [10] [11] [12] Behçet's disease, 13, 14 Cogan's syndrome, 15, 16 and ulcerative colitis 17, 18 has been reported.
MRL/lpr mice were found to spontaneously develop SNHL as well as SLE by autoimmune mechanisms. The mice carrying the lymphoproliferation (lpr) mutation have defects in the Fas gene, and a defect in negative selection of self-reactive T cells in the thymus. In cooperation with abnormal T cells, auto-reactive B cells produce autoantibodies or immune complexes which are deposited in the lesions of both the stria vascularis of the cochlea and the basement membranes of the glomeruli. [19] [20] [21] [22] It has recently been reported that SNHL in MRL/lpr mice can be improved by steroid therapy and the levels of serum immune complexes were found to be reduced after steroid therapy. 23 We have also reported that the SNHL and cochlear pathology can be transferred to normal mice by the injection of lymphocytes from MRL/lpr mice. 24 In addition, we have demonstrated that autoimmune diseases are induced by abnormal hemopoietic stem cells (HSCs). When normal mice are reconstituted with bone marrow cells or HSCs from animals with autoimmune diseases such as SLE, 25 diabetes mellitus 26 and focal and segmental glomerular sclerosis, 27 the autoimmune diseases are transferred to the normal mice. In addition, we have found that BMT can be used to treat these autoimmune diseases. 28, 29 In the present study, we show that autoimmune SNHL in MRL/lpr mice can be prevented by allogeneic BMT.
Materials and methods

Animals
MRL/lpr mice (H-2K
k ) were purchased from SLC Japan (Shizuoka, Japan). C57BL/6 (B6) (H-2K b ) mice were purchased from CLEA Japan (Osaka, Japan). These mice were maintained under specific pathogen-free conditions in our animal facilities.
Bone marrow transplantation (BMT)
The BMT procedure was previously described by Takeuchi et al. 30 Briefly, MRL/lpr mice (12 weeks of age) were intraperitoneally injected with 100 mg/kg cyclophosphamide (CY) to eliminate host-derived activated T cells. One day later, these recipient mice were lethally irradiated (fractionated radiation: 5 Gy × 2 = 10 Gy; 4 h interval) to kill the host hematolymphoid cells. Four hours after the second irradiation, the bones (the femur or tibia) of B6 mice, from which the bone marrow cells had been flushed out, were engrafted under the subcutis of the MRL/lpr mice to recruit donor-derived stromal cells, since we have previously found that alloBMT in conjunction with bone grafts (to recruit donor stromal cells) can prevent the recurrence of autoimmune diseases in MRL/lpr mice, 31 and that there is a major histocompatibility complex (MHC) restriction between pluripotent hemopoietic stem cells (P-HSCs) and stromal cells; 32 MHC-matched donor stromal cells are necessary for donor P-HSCs to proliferate. These recipient mice then received 5 × 10 7 whole bone marrow cells from B6 mice through a tail vein. One day after the first BMT plus bone grafts, the mice again received 5 × 10 7 whole bone marrow cells from B6 mice.
Auditory brainstem response (ABR)
The ABR is an evoked potential measurement of auditory activity in the brainstem, commonly used for the prediction of hearing levels in animals and young children. The ABR includes several waves: the first wave represents cochlear and auditory nerve activity, and the last waves reflect the function within the central auditory pathway. The reliability, sensitivity and non-invasive nature makes the ABR the method of choice for a first screening of hearing loss in mice.
In this study, the auditory function of MRL/lpr mice was evaluated by ABR thresholds; the procedure is described elsewhere. 24 Briefly, the mice were placed in a prone position in dark, sound-attenuated chambers which were electrically shielded and grounded. The response signals were recorded by needle electrodes which were inserted into the occiput, vertex and hindpaw (ground) after anesthesia with sodium pentobarbital (60 mg/kg, i.p.). Click stimuli (0.1 ms) were produced using a sound stimulator (MEM-4104; Nihon Kohden, Tokyo, Japan). The frequency and intensity (dBpeSPL) of the stimulus were confirmed using an oscilloscope and a calibration microphone. The stimulus was set at 20 stimulations per second. The signal was band-pass filtered at 50 to 3000 Hz and averaged 1000 times. ABRs were obtained by decreasing the stimulus in 2-dB steps from a maximum intensity of 106 dBpeSPL. The threshold was defined as the lowest intensity producing a clearly visible first wave peak. Otoscopic examination revealed that the tympanic membranes were normal in all the mice.
Statistical analyses
Data were expressed as means Ϯ s.d. The statistically significant differences in the ABR thresholds were determined using Student's paired t-test.
Flow cytometry
Spleen cells (1 × 10 6 ) were suspended in phosphate-buffered saline (PBS) containing 2% fetal calf serum (FCS) plus 0.05% sodium azide, then stained with FITC-conjugated anti-H-2K k or anti-H-2K b antibody (Ab) (Meiji Institute of Health Science, Odawara, Kanagawa, Japan) on ice. The stained cells were analyzed using a FACScan (Becton Dickinson, Mountain View, CA, USA).
Ear histology
All mice were fixed by an intracardiac perfusion of saline, followed by periodate-lysine-paraformaldehyde (PLP) under anesthesia by sodium pentobarbital. The temporal bones were removed and decalcified in 5% buffered ethylene diamine-tetra-acetate (EDTA) at 4°C for 7 days, then frozen in OCT compound (Tissue-Tek II; Lab-Tek Products, Naperville, IL, USA), sectioned into 5-m sections horizontally to the long axis of the cochlea at room temperature. Sections of tympanic cavities and cochlea were examined using hematoxylin and eosin (H&E) stain.
According to the modified indirect immunoperoxidase technique, 33 rabbit anti-mouse IgG Ab (Cappel, Organon Teknika Corporation, NC, USA) was applied to the sections immunohistochemically to detect IgG-bearing cells. The avidin-biotin complex immunostaining method was applied using anti-rabbit ABC kits (Vectastain; Vector Lab, Burlingame, CA, USA). The sections were counterstained with hematoxylin.
Kidney histology
The kidneys of the recipient mice were removed and fixed in 10% phosphate-buffered formalin. The specimens were frozen in dry-ice/acetone for the immunofluorescence study, as previously described. 30 Briefly, 3-m sections were incubated at room temperature with FITC-conjugated rabbit anti-mouse IgG or FITC-conjugated anti-mouse C3 (Medical and Biological Laboratories, Nagoya, Japan), and then washed three times with PBS. The samples were also embedded in paraffin, sectioned, and then stained with H&E.
Results
Analyses of chimerism
Flow cytometric analyses were carried out to examine the chimerism using the spleen cells from MRL/lpr mice which had been transplanted with bone marrow cells from B6 mice (abbreviated as [B6 → MRL/lpr]). More than 95% of the splenic lymphocytes from the [B6 → MRL/lpr] mice were of donor (B6) origin (H-2K b ) (Figure 1b) . The FACS pattern in the spleen cells of [B6 → MRL/lpr] mice was similar to that in the spleen cells of B6 mice (Figure 1b, c) .
ABR
The thresholds in MRL/lpr mice rose from 16 weeks of age, and progressive SNHL was observed at 24 weeks of age. On the other hand, B6 mice showed normal auditory functions even at 24 weeks of age (Figure 2) .
In this study, the auditory function of each mouse was evaluated by ABR using mice at 8 weeks of age (MRL/lpr, n = 5), 24 weeks of age (MRL/lpr and B6, n = 5) or 24 weeks after BMT ([B6 → MRL/lpr], n = 5). As shown in Table 1 , the mean thresholds in B6 mice and young (8 weeks of age) MRL/lpr mice were 18.4 and 21.1 dBpeSPL, respectively. The mean threshold in old (24 weeks of age) MRL/lpr mice was significantly higher (55.8 dBpeSPL) than those in B6 and young MRL/lpr mice. On the other hand, the threshold in [B6 → MRL/lpr] mice was 23.3 dBpeSPL, which was similar to that in B6 or young MRL/lpr mice; it was significantly lower than that in old MRL/lpr mice. These results clearly indicate that the development of SNHL can be prevented by allogeneic BMT.
Bone Marrow Transplantation
Ear histology
Histopathological studies using H&E staining revealed that the tympanic cavities were not inflamed in any of the mice, whereas non-treated MRL/lpr mice showed not only the proliferation of endothelial cells in the capillaries but also edema in the stria vascularis. However, no histopathological changes were found in the cochleae of the B6 and [B6 → MRL/lpr] mice (data not shown).
Immunohistochemical analyses of the stria vascularis were also carried out. Endothelial cells in the capillaries were positively stained with anti-IgG Ab from the basal turn to the apical turn in the stria vascularis of all five nontreated MRL/lpr mice (Figure 3b ). In contrast, no IgG deposits were observed in the cochleae of the [B6 → MRL/lpr] mice or the B6 mice (Figure 3a, c) .
Kidney histology
Immunofluorescence microscopic findings revealed that the non-treated old MRL/lpr mice showed IgG deposits in the glomeruli (Figure 4b ), whereas the [B6 → MRL/lpr] mice showed no IgG deposits in the glomeruli (Figure 4c ). B6 and young MRL/lpr mice also showed no IgG deposits (Figure 4a and data not shown). Similar findings were also obtained for C3 deposits (data not shown).
Discussion
MRL/lpr mice are well known as a murine model of SLE, and show lupus nephritis at 3-4 months of age; 50% die of uremia by 20 weeks of age. 34, 35 It has also been found that MRL/lpr mice show inner ear diseases due to the development of autoantibody or immune complex deposits. [19] [20] [21] [22] The autoantibody or immune complex deposits have been thought to be induced by auto-reactive B cells in collaboration with abnormal T cells, which have the lpr gene and the defect in the Fas gene and escape from Fas-mediated apoptosis, leading to the proliferation and activation of B cells. 36 In the present study, we treated MRL/lpr mice with CY and irradiation to eliminate the host immunocompetent cells and bone marrow cells. We then transplanted not only Bone Marrow Transplantation B6 mouse bone marrow cells but also B6 bones to recruit donor stromal cells, which can support the proliferation of donor P-HSCs, 31 since we have found that MHC-matched stromal cells are essential for P-HSCs to proliferate. (Table 1) . These findings clearly indicate that the development of SNHL in MRL/lpr mice can be prevented by allogeneic BMT.
Wobig et al 23 have recently demonstrated that the stria vascularis is the steroid-responsive site in remediation of autoimmune SNHL in MRL/lpr mice. Kusakari et al 22 have also shown that the IgG deposition and the degeneration of the stria vascularis in MRL/lpr mice at 20 weeks of age are responsible for SNHL. Therefore, it is likely that BMT prevents the development of SNHL as the result of the prevention of immune complex deposits on the stria vascularis in the cochleae. Although B6 mice show presbycusis at high frequencies (over 4000 Hz), with the degeneration of the outer hair cells and spiral ganglion cells in the basal turn of the cochleae from 28 weeks of age, 37 we used B6 mice at 24 weeks of age and applied a clicking stimulus with the signal band-pass filtered at low frequency (50 to 3000 Hz) in ABR. No abnormal findings were found in the tympanic membranes or tympanic cavities in any mice used in this study.
In humans, it has been reported that autoimmune diseases such as autoimmune thyroiditis, [38] [39] [40] Graves' disease, 41 insulin-dependent diabetes mellitus 42, 43 and myasthenia gravis 44, 45 are transferred to recipients after BMT. It has also been reported that autoimmune diseases such as psoriasis vulgaris, 46, 47 ulcerative colitis 46 and palmoplantar pustular psoriasis 40 are resolved after BMT in patients suffering from both leukemia and autoimmune diseases. Based on these findings, we have proposed a new concept of 'stem cell disorders.' 48 Regarding the etiopathogenesis of autoimmune diseases, our current hypothesis is as follows: polygene abnormalities primarily exist at the gene level of P-HSCs. Endogenous or exogenous retroviruses are probably involved in the development of P-HSC abnormalities. Autoreactive immunocompetent cells, including T cells, differentiate from the abnormal P-HSCs. In systemic autoimmune diseases, autoreactive T cells attack various organs, as seen in chronic graft-versus-host reaction (GVHR), resulting in systemic tissue injury. Auto-antibody-producing B cells develop from the abnormal HSCs, resulting in the deposition of antibodies and immune complexes in the endothelium.
Prospective studies reported that approximately 8 to 48% of patients with systemic autoimmune disease, including SLE and RA, demonstrate hearing disturbance. 9, 10, 12 SNHL by an autoimmune mechanism usually develops bilaterally and progressively. Highly progressive bilateral hearing disturbance, as well as other major symptoms of autoimmune disease, would cause patients to suffer.
In the present study, we have demonstrated that both autoimmune SNHL and SLE in MRL/lpr mice can be prevented by BMT. To our knowledge, this is the first report indicating that alloBMT can be used to prevent the progress of SNHL. Therefore, it is likely that allogeneic BMT, which replaces the abnormal HSCs with normal HSCs and reconstitutes the recipient immune system, or autologous BMT using genetically modified bone marrow cells, has a curative effect on inner ear autoimmune dysfunction associated with systemic autoimmune diseases.
